Abstract PS5-08-18: Trofuse-011: a phase 3, randomized, open-label study of sacituzumab tirumotecan with or without pembrolizumab vs treatment of physician’s choice for previously untreated locally recurrent unresectable or metastatic triple-negative breast cancer